Uterine Fibroids and PHRT: Are Leiomyomas a Contraindication to Hormone Restoration?
One of the more challenging questions in perimenopausal hormone management is what to do when a woman needs hormonal support but already has hormone-responsive uterine pathology.
Consider this clinical scenario:
A 46-year-old perimenopausal woman presents with increasingly irregular bleeding, at times experiencing two bleeding episodes per month. She has a history of ADD, depression, and anxiety and had previously been treated with topical testosterone and oral progesterone.
Her previous regimen included:
- Testosterone topical 2.5 mg/mL daily
- Progesterone 150 mg sustained-release capsule nightly
- DIM 150 mg daily
She discontinued her hormones and underwent pelvic ultrasound.
The ultrasound demonstrated a leiomyomatous uterus, an endometrial thickness of approximately 6.8 mm, multiple right ovarian cysts with the largest measuring 2.5 cm, and a small amount of free fluid.
The clinical question was straightforward:
Can a patient with uterine leiomyomas still be considered for Physiologic Hormone Restoration Therapy (PHRT)?
The answer is more nuanced than simply yes or no.
Fibroids Are Not Automatically a Contraindication to Hormone Restoration
Uterine leiomyomas, commonly called fibroids, are hormonally responsive. Understandably, this can make clinicians reluctant to use hormone therapy in women who have them.
But the presence of a fibroid does not necessarily mean that a woman should be excluded from hormone restoration.
The more important questions are:
What are the fibroids doing clinically? Is the patient experiencing abnormal uterine bleeding? Is there other uterine pathology? And has the bleeding been adequately evaluated?
Several physicians within the Women’s Hormone Network Clinical Advisory Team report managing substantial numbers of women with fibroids while using PHRT.
Dr. James Nagel noted:
“The majority of my patients have uterine fibroids. As long as the fibroids are asymptomatic and do not cause dysfunctional uterine bleeding, they can live with the fibroids for years.”
He also emphasized that these patients may still experience meaningful improvements in quality of life and other health parameters with hormone restoration.
That distinction becomes particularly important in this case because the patient is already experiencing frequent bleeding.
The Bleeding Comes Before the Hormones
Before asking how to dose estrogen or progesterone, the clinician should first address the abnormal bleeding.
A 46-year-old woman experiencing two bleeding episodes per month should not simply have that bleeding attributed to perimenopause or fibroids without appropriate evaluation.
Her ultrasound provides useful information, but the clinician still needs to determine whether her bleeding pattern and individual risk factors warrant further gynecologic evaluation before hormone therapy is initiated or restarted.
This is an important principle of PHRT:
Hormone restoration should not be used to bypass the evaluation of underlying pathology.
Once concerning pathology has been reasonably excluded, however, the conversation can shift from whether hormones can be used to how they should be used.
The Goal Is Not Simply to “Add Estrogen”
PHRT is fundamentally different from approaching this patient by simply adding estrogen to her existing continuous hormone regimen.
The objective is to recreate hormonal signaling in a rhythmic, physiologic pattern, while carefully observing the response of the uterus and the patient’s bleeding pattern.
Progesterone becomes particularly important in a woman with an intact uterus.
Emily Sadri, NP reports extensive clinical experience treating women with fibroids using rhythmic estrogen combined with higher-dose vaginal progesterone.
In her practice, vaginal progesterone may be dosed in a 300-400-300 mg rhythmic pattern for 15 days each month, with twice-daily dosing sometimes used depending upon the clinical situation.
This should not be interpreted as a universal treatment protocol for uterine fibroids. Rather, it illustrates an important clinical concept: women with uterine pathology may require individualized progesterone strategies and careful monitoring rather than simply applying a standard hormone regimen.
Look Beyond the Fibroid
Another important lesson from this case is that PHRT should not occur in isolation.
Fibroids are hormonally responsive, but the broader biological environment matters as well.
The clinical material reviewed by the team emphasizes that oxidative stress, nutrient status, tissue differentiation, oxygen delivery, and extracellular-matrix behavior may all contribute to the clinical picture surrounding fibroids.
This is why several members of the Clinical Advisory Team recommended addressing pathways involved in estrogen metabolism and elimination alongside hormone restoration.
Depending upon the individual patient, this might include attention to adequate dietary fiber, glutathione and hepatic support, iodine status when clinically appropriate, gastrointestinal health, and estrogen metabolism.
Dr. ACE also suggested assessing intestinal beta-glucuronidase when clinically appropriate and considering targeted support such as calcium-D-glucarate based upon the findings.
The goal is not to “detox estrogen” indiscriminately. It is to recognize that hormone metabolism, conjugation, intestinal elimination, and recirculation can influence the hormonal environment in which therapy is being provided.
What Should We Monitor?
If PHRT is ultimately initiated, this is a patient who deserves closer clinical observation.
Bleeding patterns should be documented carefully. Changes in pelvic pressure, pain, menstrual volume, or duration should prompt reassessment. Depending upon her clinical course, repeat imaging may also be appropriate.
The objective is not merely to normalize a laboratory value.
The objective is to restore physiologic hormonal signaling while continually asking whether the uterus, and the patient as a whole, is responding appropriately.
The Clinical Takeaway
A diagnosis of uterine leiomyomas should not automatically disqualify a perimenopausal woman from PHRT.
But it should change the level of clinical attention.
In a woman with asymptomatic fibroids and no abnormal uterine bleeding, PHRT may remain a reasonable option with appropriate monitoring.
In a woman like this patient, who is already experiencing frequent abnormal bleeding, the bleeding should be appropriately evaluated before hormone restoration is initiated or resumed.
Once concerning pathology has been excluded, a carefully individualized PHRT approach can be considered – incorporating rhythmic hormone signaling, adequate progesterone support, attention to estrogen metabolism and elimination, and close observation of the patient’s uterine response.
Perhaps the most important lesson is this:
The presence of fibroids does not necessarily tell us to stop thinking about hormones. It tells us that we need to think about them more carefully.
This case discussion is intended for healthcare-professional education and does not establish a universal treatment protocol. Hormone therapy and abnormal uterine bleeding should be evaluated and managed according to the individual patient’s history, examination, diagnostic findings, and clinical risk factors.
